SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Larry Liebman who wrote (67)11/16/1999 12:53:00 PM
From: scaram(o)uche  Read Replies (3) of 447
 
"Pfizer also has an anti-cancer drug in Phase II trials. The substance
selectively inhibits the so-called
EGFR receptor. Pfizer said separate trials of the drug were being conducted
against ovarian, head
and neck, and non-small cell lung cancer, adding it was studying oral and
injectable formulas. It plans
to move the drug into more advanced trials in mid-2000."

(thanks, J.)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News